drugset / Trial / NCT05913661
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2
Unknown
30 enrolled
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University · collabShenzhen University General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma.
Timeline
- Start
- 2023-07
- Primary completion
- 2024-11
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | 13.5 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |